Skip to content
★ Sign in to follow
SH

Shanghai Haohai Biological Technology Co., Ltd. Stock: price and insider trades · China

昊海生科

CN·Mcap CN¥6.6BHealth Care

No insider purchase over the last 90 days. The latest, by 蒋丽霞, was filed 27 Jun 2023.

Shanghai Haohai Biological Technology Co., Ltd.: what insiders have been doing

Shanghai Haohai Biological Technology Co., Ltd. belongs to the Health Care sector. Filings by its managers are published through SSE / SZSE (CSRC). From 4 November 2025 to 4 November 2026, the disclosure feed for Shanghai Haohai Biological Technology Co., Ltd. logged 3 filings by 1 insider.

The flow runs one way only: 3 sales worth €30k, from 1 insider, and no purchase. At €17k, the sale published on 29 June 2026 by 刘璐 is the largest of the period.

With 3 filings in twelve months, the company is more active than the median of 2 filings across the 517 companies we follow on the same exchange. The full history, which starts in 2023, counts 1 purchase against 8 sales.

Most trades are made public on the day they happen. Until a filing is published, the market cannot know about the trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.

Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and UCB. Source: insider filings from SSE / SZSE (CSRC). Past trades are no guide to future returns.

Insider Decl.
9
Thresholds
n/a
Buy Volume
€9,949
1 ops. · all time
Sell Volume
€4M
8 ops. · all time

Who traded when

BuySale
刘璐3 sales
甘人宝2 sales

Since the insiders bought

  • Filed 27 Jun 2023 · 1230 days ago · €9,949
    +9.1%
    Entry CN¥56.91 · Close at T+365 CN¥62.10

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 10,237 of 26,912 companies
57.5
score / 100
Value
50
Quality
65
FCF yld4.5%
Earn yld3.7%
EV/EBITDA15.3x
ROE1.3%
Gross mgn70%
Net mgn10%
Debt/EBITDA0.9x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

CN¥29.48
Analyst consensus
1 analysts
·
CN¥45.00Target CN¥45.00(+53%)CN¥45.00
Income statement
RevenueCN¥2.4B
Gross profitCN¥1.7B70% margin
EBITDACN¥464.9M19% margin
Net incomeCN¥251M4.8% margin
Valuation
PER (trailing)44.7x
P/Book1.3x
Beta0.43
Balance sheet & cash
Market capCN¥6.6B
Total debtCN¥398.5M
Free Cash FlowCN¥304M
Debt / Equity8%
Profitability & ownership
ROE1.3%
ROA0.8%
% insiders73.6%
% institutions0.4%
Last declaration on 26 October 2026
Declarations9 total
  • ▼
    核心技术人员Executives
    25,048 CNY4SSE
    800 shares@ CN¥234.295611.1% of flowA股XSHGSSE:273000001780133120
  • ▼
    核心技术人员Executives
    131,805 CNY9SSE
    4,500 shares@ CN¥227.229163.2% of flowA股XSHGSSE:273000000772888500
  • ▼
    核心技术人员Executives
    78,880 CNY6SSE
    2,000 shares36.8% of flowA股XSHGSSE:273000000524335140
  • ▼
    核心技术人员Executives
    11M CNY6SSE
    176,000 shares39.9% of flowA股XSHGSSE:173000008693712300
  • ▼
    核心技术人员Executives
    6M CNY4SSE
    89,644 shares21.3% of flowA股XSHGSSE:173000008679725060
  • ▼
    核心技术人员Executives
    8M CNY5SSE
    86,856 shares28.6% of flowA股XSHGSSE:173000008139919970
  • ▼
    核心技术人员Executives
    478,500 CNY10SSE
    5,000 shares100.0% of flowA股XSHGSSE:173000007715424740
  • ▼
    核心技术人员Executives
    3M CNY3SSE
    27,500 shares10.2% of flowA股XSHGSSE:173000006838121800
  • ▲
    核心技术人员Executives
    78,800 CNY10SSE
    1,000 shares100.0% of flowA股XSHGSSE:173000006685315100
    Canonical exit: 25 Sept 2023 (T+90)

9 of 9 declarations

About Shanghai Haohai Biological Technology Co., Ltd.

昊海生科 is a company in the health and pharmaceutical sector, listed on the XSHG market. It focuses on the development and production of innovative pharmaceutical products.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations